With VERTIS SITA2 On Board, Merck Eyes Broad Initial Approval For Ertugliflozin

In an interview at the European Association for the Study of Diabetes meeting, Merck exec Sam Engel explains the rationale behind the clinical trial strategy for the SGLT-2 inhibitor ertugliflozin, as it gears up with partner Pfizer for filings by the end of this year.